Jones Financial Companies Lllp Cuts Stock Position in Becton, Dickinson and Company $BDX

Jones Financial Companies Lllp lowered its stake in Becton, Dickinson and Company (NYSE:BDX) by 50.9% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 184,723 shares of the medical instruments supplier’s stock after selling 191,704 shares during the quarter. Jones Financial Companies Lllp owned 0.07% of Becton, Dickinson and Company worth $28,794,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in BDX. Auto Owners Insurance Co raised its stake in Becton, Dickinson and Company by 22,225.2% in the 4th quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock valued at $790,079,000 after purchasing an additional 40,528,680 shares during the last quarter. BlackRock Inc. purchased a new stake in Becton, Dickinson and Company during the 2nd quarter valued at about $3,721,533,000. Wellington Management Group LLP grew its stake in Becton, Dickinson and Company by 9,056.3% during the 3rd quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier’s stock valued at $979,290,000 after acquiring an additional 5,174,944 shares in the last quarter. Vanguard Group Inc. raised its holdings in Becton, Dickinson and Company by 13.0% in the 4th quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier’s stock valued at $7,118,282,000 after acquiring an additional 4,223,149 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its stake in Becton, Dickinson and Company by 23,219.2% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 4,155,709 shares of the medical instruments supplier’s stock worth $769,397,000 after purchasing an additional 4,137,888 shares in the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Trading Down 0.7%

Shares of NYSE BDX opened at $190.58 on Tuesday. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $52.51 billion, a PE ratio of 57.40, a PEG ratio of 13.53 and a beta of 0.19. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $193.07. The stock has a fifty day simple moving average of $162.48 and a 200-day simple moving average of $160.73.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, beating the consensus estimate of $3.14 by $0.09. The company had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.Becton, Dickinson and Company’s revenue was up 5.4% compared to the same quarter last year. During the same period in the previous year, the company posted $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, equities analysts forecast that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be issued a $1.05 dividend. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 126.51%.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. Evercore set a $180.00 price target on Becton, Dickinson and Company in a research report on Monday, July 6th. Weiss Ratings restated a “sell (d+)” rating on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. The Goldman Sachs Group decreased their target price on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a report on Wednesday, May 27th. UBS Group began coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, July 28th. They issued a “buy” rating and a $190.00 price target for the company. Finally, Citigroup restated a “buy” rating on shares of Becton, Dickinson and Company in a research report on Thursday, August 13th. Eight equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Hold” and a consensus target price of $185.67.

Insider Activity at Becton, Dickinson and Company

In related news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the firm’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the sale, the chief executive officer owned 110,163 shares of the company’s stock, valued at $20,380,155. This trade represents a 3.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the completion of the sale, the executive vice president directly owned 13,172 shares in the company, valued at approximately $1,918,633.52. This represents a 7.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 11,704 shares of company stock worth $1,963,618. Company insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.